Savara Inc APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Savara Inc (SVRA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $7.76 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-11
- Savara Inc apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $7.76M, a 190.93% increase year-over-year.
- Savara Inc apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $10.73M, a 260.94% increase year-over-year.
- Savara Inc apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $3.42M, a 44.45% increase year-over-year.
- Savara Inc apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.67M, a 21.54% increase year-over-year.
- Savara Inc apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $14.42M, a 46.26% increase from fiscal 2024.
- Savara Inc apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $9.86M, a 136.00% increase from fiscal 2023.
- Savara Inc apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $4.18M, a 104.70% increase from fiscal 2022.
- Savara Inc apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $2.04M, a 37.39% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.76M 10-Q · filed 2026-08-11 | $18.49M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $10.73M 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $14.42M 10-K · filed 2026-03-13 | |||
| 2025-09-30 | $3.42M 10-Q · filed 2025-11-12 | $6.09M derived: sum of 2 quarters · filed 2026-08-11 | $9.07M derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-06-30 | $2.67M 10-Q · filed 2026-08-11 | $5.64M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $2.97M 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $9.86M 10-K · filed 2026-03-13 | |||
| 2024-09-30 | $2.37M 10-Q · filed 2025-11-12 | $4.57M derived: sum of 2 quarters · filed 2025-11-12 | $6.82M derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | $2.20M 10-Q · filed 2025-11-12 | $4.45M derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | $2.26M 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $4.18M 10-K · filed 2025-03-27 | |||
| 2023-09-30 | $995.00K 10-Q · filed 2024-11-12 | $1.95M derived: sum of 2 quarters · filed 2024-11-12 | $2.82M derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $958.00K 10-Q · filed 2024-11-12 | $1.82M derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $864.00K 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $2.04M 10-K · filed 2024-03-07 | |||
| 2022-09-30 | $450.00K 10-Q · filed 2023-11-09 | $906.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.48M derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $456.00K 10-Q · filed 2023-11-09 | $1.03M derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $574.00K 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $3.26M 10-K · filed 2023-03-30 | |||
| 2021-09-30 | $690.00K 10-Q · filed 2022-11-10 | $1.46M derived: sum of 2 quarters · filed 2022-11-10 | $2.41M derived: sum of 3 quarters · filed 2022-11-10 | |
| 2021-06-30 | $771.00K 10-Q · filed 2022-11-10 | $1.72M derived: sum of 2 quarters · filed 2022-11-10 | ||
| 2021-03-31 | $946.00K 10-Q · filed 2022-11-10 | |||
| 2020-12-31 | $5.11M 10-K · filed 2022-03-30 | |||
| 2020-09-30 | $1.93M 10-Q · filed 2021-11-12 | $3.11M derived: sum of 2 quarters · filed 2021-11-12 | $4.30M derived: sum of 3 quarters · filed 2021-11-12 | |
| 2020-06-30 | $1.18M 10-Q · filed 2021-11-12 | $2.37M derived: sum of 2 quarters · filed 2021-11-12 | ||
| 2020-03-31 | $1.19M 10-Q · filed 2021-11-12 | |||
| 2019-12-31 | $4.44M 10-K · filed 2021-03-10 | |||
| 2019-09-30 | $1.15M 10-Q · filed 2020-11-05 | $2.29M derived: sum of 2 quarters · filed 2020-11-05 | $3.29M derived: sum of 3 quarters · filed 2020-11-05 | $4.24M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $1.15M 10-Q · filed 2020-11-05 | $2.15M derived: sum of 2 quarters · filed 2020-11-05 | $3.09M derived: sum of 3 quarters · filed 2020-11-05 | $5.08M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-03-31 | $1.00M 10-Q · filed 2020-11-05 | $1.95M derived: sum of 2 quarters · filed 2020-11-05 | $3.93M derived: sum of 3 quarters · filed 2020-11-05 | $4.33M derived: sum of 4 quarters · filed 2020-11-05 |
| 2018-12-31 | $945.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $2.93M derived: sum of 2 quarters · filed 2020-03-12 | $3.33M derived: sum of 3 quarters · filed 2020-03-12 | $3.74M 10-K · filed 2020-03-12 |
| 2018-09-30 | $1.99M 10-Q · filed 2019-11-07 | $2.38M derived: sum of 2 quarters · filed 2019-11-07 | $2.79M 10-Q · filed 2018-11-07 | $2.99M derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | $392.00K 10-Q · filed 2019-11-07 | $804.00K 10-Q · filed 2018-08-09 | $1.01M derived: sum of 3 quarters · filed 2019-11-07 | $1.12M derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-03-31 | $412.00K 10-Q · filed 2019-11-07 | $614.00K derived: sum of 2 quarters · filed 2019-11-07 | $728.00K derived: sum of 3 quarters · filed 2019-11-07 | |
| 2017-12-31 | $202.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $316.00K derived: sum of 2 quarters · filed 2019-03-13 | $552.00K 10-K · filed 2019-03-13 | |
| 2017-09-30 | $114.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $350.00K 10-Q · filed 2017-11-08 | ||
| 2017-06-30 | $236.00K 10-Q · filed 2017-08-09 | |||
| 2016-12-31 | $209.00K 10-K · filed 2018-03-14 | |||
| 2015-12-31 | $153.00K 10-K · filed 2018-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |